tbuckley/cabot-search huggingface dataset:
Abstract 1935: EBP50 inhibits breast cancer cell proliferation by blocking EGFR phosphorylation
Authors: Junfang Zheng, Wenfang Yao, Duiping Feng, Weihua Bian, Ying Xiong, Xiaomei Yang, Longyan Yang, Yunying Zhou, Renyou Zhai, Junqi He
Journal: Cancer Research (2011)

Abstract EBP50 (Ezrin-radixin-moesin-binding phosphoprotein-50, also known as NHERF, NHERF1) has been reported to interact with epidermal growth factor receptor (EGFR) and enhance EGFR activity and its downstream ERK signaling in a cervical cancer cell line HeLa. However, our previous results demonstrated that EBP50 could suppress breast cancer cell proliferation, suggesting its inhibitory effect on EGFR signaling in breast cancer cell. So we detected the effect of EBP50 expression on EGF-induced cell proliferation and the activation of EGFR signaling in breast cancer cell lines, MDA-MB-231 and MCF-7. In MDA-MB-231 cells which expressed low level of EBP50, EBP50 over-expression inhibited EGF-induced cell proliferation. In MCF-7 cells which expressed high level of EBP50, EBP50 knockdown promoted EGF-induced cell proliferation. EBP50 was reported to interact with EGFR via its carboxyl terminal regulatory domain, which is adjacent to the autophosphorylation domain of the receptor, so it is possible that the association of EBP50 and EGFR mask the phosphorylation site of EGFR so as to prevent EGFR activation. To test this hypothesis, we detected the phosphorylation status of EGFR in the presence or absence of the EBP50 expression. Over-expression of EBP50 in MDA-MB-231 inhibits EGF-stimulated EGFR phosphorylation, and knockdown of EBP50 in MCF-7 cells led to the enhanced EGF-stimulated EGFR phosphorylation. Meanwhile, the total expression levels of EGFR were not affected by the different expression level of EBP50 during EGF stimulation. In the case of EBP50 expression on the EGFR downstream signaling, EBP50 over-expression inhibited EGF-stimulated ERK activity in MDA-MB-231 cells, and EBP50 knockdown resulted in the enhanced EGF-stimulated ERK activity in MCF-7 cells. These data are consistent with results of MDA-MB-231 and MCF-7 cell lines pretreated with EGFR tyrosine kinase inhibitor-AG1478, that EGF-stimulated ERK activity was inhibited when EGFR phosphorylation was blocked. Taken together, our results demonstrated that EBP50 can suppress EGF-induced proliferation of breast cancer cells by retarding EGFR phosphorylation and blocking EGFR downstream signaling in breast cancer cells. These results provide further insights into the molecular mechanism by which EBP50 regulates the development and progression of breast cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1935. doi:10.1158/1538-7445.AM2011-1935
FRI0036 Failing to Achieve Low Disease Activity during the First Year of Early Arthritis is an Independent Predictor of Work Disability at 5 Years: Results from the ESPOIR Cohort: Table 1.
Authors: S. Dadoun, B. Combe, A. Saraux, B. Fautrel, L. Gossec
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Rheumatoid arthritis has an important impact on work; more than 10% patients are already in work disability after 3 years of disease. Baseline factors strongly predict this disability. Early and tight control improves disease activity: does this have consequences on later work disability? <h3>Objectives</h3> To assess the impact of being in low disease activity (DAS28&lt;3.2) at 6 months and/or 12 months on work disability at five years, after adjusting on baseline predictive factors of work disability. <h3>Methods</h3> Early arthritis (EA) patients from the ESPOIR cohort who were under 60 years old, had a paid job at baseline and did not miss any follow-up visits were included in the study. For this analysis, the outcome of interest was work disability at 5 years. Predictive factors of work disability were analysed: (a) based on baseline variables including demographic factors, job characteristics, disease activity and severity factors (DAS28, HAQ, rheumatoid factor/antiCCP positivity, erosions on XRay, fulfilling the ACR/EULAR criteria, CRP), and quality of life (SF-36). (b) The second model included on top of the above variables, the fact of having DAS28&lt;3.2 at least once at the 6 or 12 months follow up visits. (c) The third model included on top of model (a), having a DAS28&lt;3.2 twice (at 6 and 12 months both). Statistics used univariate and multivariate logistic regression. <h3>Results</h3> Among the 331 patients included (76.7% female, mean age 45.7 yrs, DAS28 at baseline: 5.1), 56 patients (16.9%) were in disability at 5 years. Low disease activity was achieved at least once for 230 patients (69.5%) and twice for 129 patients (39.0%) during the first year. Low disease activity once or twice during the first year of disease was an independent predictive factor of not being disabled at five years with odds ratios of 0.17 [0.08;0.33] and 0.17 [0.06;0.45] respectively (Table). <h3>Conclusions</h3> Achieving LDA at least once during the first year of follow up was an independent predictive factor of less work disability at 5 years in early arthritis with a 5-fold decreased risk of disability, even after adjusting on the baseline variables. This suggests there is a window of opportunity for job retention during the first year by controlling disease activity. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3123
Abstract P3-04-12: BreastMark: An integrated approach to mining publically available Transcriptomic Datasets relating to Breast Cancer Outcome
Authors: S Madden, P Gaule, C Clarke, ST Aherne, N O'Donovan, M Clynes, J Crown, WM Gallagher
Journal: Cancer Research (2012)

Abstract Background: Breast cancer is a complex heterogeneous disease for which a substantial resource of transcriptomic data is available. Indeed, gene expression data have facilitated the division of breast cancer into, at least, five molecular subtypes, Luminal A, Luminal B, Her2, Normal-like and Basal. Once identified, breast cancer subtypes can inform clinical decisions surrounding patient treatment and prognosis. It is important to identify patients at risk of developing aggressive disease so as to tailor the level of clinical intervention. Methods: We have developed a user-friendly web-based system to allow the identification and evaluation of genes that are significantly associated with disease progression and survival for breast cancer in general and also with respect to molecular subtype. The underlying algorithm combines gene expression data from multiple DNA microarray experiments and detailed clinical data to correlate outcome with gene expression levels. This algorithm integrates gene expression and survival data from 21 datasets on 10 different microarray platforms corresponding to 20,017 gene sequences across 3,519 samples. Results: We demonstrate the robustness of our approach in comparison to two commercially available prognostic tests in breast cancer. Our algorithm complements these prognostic tests and is consistent with their findings. In addition, BreastMark can act as a powerful reductionist approach to these more complex gene signatures, eliminating superfluous genes, potentially reducing the complexity and cost of these multi-index assays. We also applied the algorithm to examine expression of 58 receptor tyrosine kinases in the basal-like subtype of breast cancer, identifying seven receptor tyrosine kinases associated with poor disease-free survival and/or overall survival in this subtype (EPHA5, FGFR1, FGFR3, VEGFR1, PDGFRβ, ROS, TIE1). A web application for using this algorithm is currently available at http://glados.ucd.ie/BreastMark/index.html. Conclusions: BreastMark is a useful tool for examining putative prognostic markers at the RNA level in breast cancer. The value of this tool will be in the preliminary assessment of putative biomarkers in breast cancer as a whole and within its molecular subtypes. It will be of particular use to clinical and academic research groups with limited bioinformatics facilities. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-04-12.
Sister Mary Joseph Nodules on 99mTc HYNIC-TOC Scintigraphy in Patients With Neuroendocrine Tumors
Authors: Hongli Jing, Yingqiang Zhang, Fang Li
Journal: Clinical Nuclear Medicine (2014)

A Sister Mary Joseph nodule represents an umbilical metastasis, which is more commonly caused by a primary malignancy in gastrointestinal tract or from reproductive system. We report Sister Mary Joseph nodules caused by neuroendocrine tumor and revealed on Tc HYNIC-TOC scintigraphy.
Abstract B56: Organelle targeted photodynamic therapy
Authors: Shanta Dhar
Journal: Cancer Research (2011)

Abstract The success of a cancer treatment is directly related to its ability to selectively kill cancer cells. Photodynamic therapy (PDT) with a photosensitizer (PS) that targets mitochondria causes a prompt release of cytochrome c into the cytoplasm and activation of caspases-9 and -3, among other caspases, that are responsible for initiating cell degradation. Photofrin is the FDA approved drug for PDT. Mitochondria have repeatedly been implicated as primary targets of porphyrin mediated PDT. However, a systematic study to direct the PDT drugs towards their cellular target, mitochondria of the cancer cell, is not yet fully explored. Phthalocyanins (Pc) are a class of compounds, which are known to successfully address the drawbacks exhibited by the porphyrin-based compounds. PDT, using the second-generation Pc, causes mitochondrial damage and induces apoptosis. However, the Pc molecules are hydrophobic and must be encapsulated within a liposomal formulation for successful delivery. Given that most effective PDT drug candidates act on the mitochondria of cancer cells and their hydrophobicity require suitable delivery vehicles for their intracellular accumulation, we hypothesize that the construction of engineered targeted drug delivery systems to direct PDT drugs to the mitochondria of the cancer cells would allow an effective phototherapeutic action. This would result in a higher local concentration of singlet oxygen in the mitochondria of cancer cells. In order to study this hypothesis, we have initiated the synthesis of a series of mitochondria targeting polymers to study nanoparticle (NP) assisted targeted delivery and anticancer properties of metallo phthalocyanins. The synthesis and biological activity of these constructs will be discussed. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the Second AACR International Conference on Frontiers in Basic Cancer Research; 2011 Sep 14-18; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2011;71(18 Suppl):Abstract nr B56.
SP0220 Peer and Research Support in Rare Diseases – A CASE Study from the AKU Society
Authors: L. Wagner
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> Alkaptonuria (AKU) is an ultra-rare inheritable metabolic disease resulting in a 2000-fold accumulation of the intermediate product homogentisic acid (HGA). Oxidation of HGA by air or within the connective tissue causes darkening of the urine, pigmentation of eyes and ears, kidney- and prostrate-stones, aortic stenosis, but most severely an early onset of osteoarthritis called ochronotic arthropathy (ochronosis) due to blackening of the cartilage. Ochronosis is very painful, disabling and progresses very rapidly. It starts in the third decade with the spine and affects the large joints in the fourth decade with patients frequently requiring several joint replacements between the fifth and sixth decade. Like many of the more than 400 rare rheumatic and musculoskeletal diseases (RMD9s), AKU-patients undergo a long odyssey of several years until their diagnosis and experience few medical treatments as little information is available. Thus, AKU-patients often feel isolated from society as well as medical and governmental support due to lack of understanding. Hence, peer support and research has become indispensable for the physical and psychological well-being of AKU-patients. Research of the natural history of AKU at the NIH (USA), Piestany and Bratislava (Slovakia), Liverpool (UK), Siena (Italy) and Vellore (India) has given a better understanding of the cause and progress of the disease. Establishing AKU-societies in UK (AKU-Society Ltd), France (ALCAP), Italy (AimAKU), USA &amp; Canada (AKU Society of North America), Germany (DSAKU e.V.) as well as Slovakia, Netherlands, Jordan, Belgium and India enable national peer support, with AKU-Patient workshops being extremely well received. Social media such as internet, facebook and forums supply information and enable exchange and advice between patients on an international platform. Based on knowledge and experience, the national organisations of PARE are able to give local advice and practical support on pain management, exercises, working with osteoarthritis and social benefits, while in return the AKU-Societies supply information on the disease and special needs of AKU-Patients. Events such as world arthritis day and rare disease day give the opportunity to raise public awareness within society. International conferences such as EULAR and ECRD allow medical experts and scientist to have access on the differential diagnostics of AKU. Finally the overall network enables the development of a treatment for AKU-patients. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6233
Diagnosis of Horseshoe Kidney Not Shown on Ultrasound But Clearly Visualized by Renal Scintigraphy
Authors: M Reddy, Y Studentsova, V Saranoff, I Zanzi, D Margouleff
Journal: Clinical Nuclear Medicine (2000)

Nephrosonography was performed on a 4-day-old boy, which showed a small right kidney but did not visualize the left kidney. Renal scintigraphy was requested to assess congenital absence or ectopia of the left kidney. Renal scintigraphy with Tc-99m MAG3 revealed both kidneys, which were fused inferiorly (i.e., a horseshoe kidney). Other investigators have reported that renal scintigraphy is more accurate than sonography in identifying ectopic renal tissue.
Diagnosis of Adrenal Disease by Visualization of Human Adrenal Glands with<sup>131</sup>I-19-Iodocholesterol
Authors: Lionel M. Lieberman, William H. Beierwaltes, Jerome W. Conn, Azizullah N. Ansari, Hiroshi Nishiyama
Journal: New England Journal of Medicine (1971)

Normally functioning adrenal glands in four patients were readily visualized with the Anger camera and a rectilinear photoscanner after administration of 131I-19-iodocholesterol. Three patients with Cushing's syndrome due to ACTH excess showed adrenal glands approximately equal in size and radioactivity concentration. In a patient with persistent Cushing's syndrome after bilateral total adrenalectomy radioactivity was concentrated in the region of the right adrenal bed compatible with a functioning adrenal remnant. A right adrenal adenoma in a patient with Cushing's syndrome measured 3.5 by 3.0 cm on scan, with no uptake in the opposite gland. At surgery, the adenoma measured 3.5 by 3.0 by 2.7 cm. In two patients, one with a 112-g pheochromocytoma and one with extensive calcifications of one adrenal gland, the involved gland was not imaged, but "normal" adrenal images of the normal contralateral glands were shown.
Abstract P5-03-07: Adiponectin Deficiency Accelerated Breast Cancer Development and Promoted Cholesterol Accumulation in Mammary Tumors of MMTV-Polyomavirus Middle T Antigen Mice
Authors: J Liu, A Xu, Y. Wang
Journal: Cancer Research (2010)

Abstract Breast cancer is the most common cancer in women. Visceral obesity and body weight gain are associated with the increased risk of postmenopausal breast cancer. Adiponectin is an adipokine possessing anti-tumor activities against various types of obesity-related cancers. The present study has established a MMTV-polyomavirus middle T antigen (PyVT) transgenic mouse deficient with adiponectin (ADN) expression. Compared to the control mice [PyVT(+/−)ADN(+/+)], the development of mammary tumors in mice lacking this adipokine [PyVT(+/−)ADN(-/-)] was significantly accelerated. While the serum total cholesterol was progressively decreased from week 11 onwards, the cholesterol content in tumor tissues was elevated in both types of mice. The ratio between serum LDL-cholesterol and HDL-cholesterol was significantly higher in PyVT(+/−)ADN(-/-) mice than that in PyVT(+/−)ADN(+/+) mice. Adiponectin was able to inhibit cholesterol uptake in both MDA-MB-231 human breast cancer cells and the primary tumor cells isolated from PyVT transgenic mice. These data demonstrated that the anti-breast cancer activity of adiponectin was at least in part attributed to its suppressive effects on cholesterol accumulation in mammary tumors. This work is supported by Research Grants Council of Hong Kong (Project no.777908M). Adiponectin knockout mice were kindly provided by Dr. Lawrence Chan at Baylor College of Medicine, who generated these mice with the support of the US National Institutes of Health grant HL-51586. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-03-07.
Arteriovenous Fistula after Percutaneous Needle Biopsy — Surgical Repair with Preservation of Renal Function
Authors: Elliot Leiter, Donald Gribetz, Seymour Cohen
Journal: New England Journal of Medicine (1972)

PERCUTANEOUS renal biopsy has become an established diagnostic technic in the evaluation of both adults and children with parenchymal renal disease. Although complications are few,1 the increasing use of renal arteriography has demonstrated an appreciable incidence of arteriovenous fistula after biopsy.2 , 3 Most fistulas are small and disappear spontaneously,3 4 5 but there are several reports of hemorrhage or hypertension requiring operative intervention.6 7 8 9 10 11 Renal exploration has most often resulted in nephrectomy,7 8 9 although there are occasional reports of partial nephrectomy with preservation of the uninvolved portion of the kidney.10 , 11 The case reported below illustrates the extent of hemorrhage that can occur after renal biopsy. . . .
Abstract 137: Racial differences in physical activity after breast cancer diagnosis.
Authors: Brionna Hair, Sandi Hayes
Journal: Cancer Research (2013)

Abstract Background: The established benefits of physical activity (PA) after breast cancer diagnosis, including reduced mortality and treatment-related side effects and improved quality of life, suggest that PA should become a component of breast cancer care. Research shows that breast cancer survivors decrease PA post-diagnosis, but these studies have been underpowered to examine racial differences or were not population-based. Methods: The Carolina Breast Cancer Study, a population-based study of incident breast cancer cases, assesses PA levels pre- and post-diagnosis in a large sample (n=1,735) with a substantial proportion of African-Americans (21%). PA was calculated as the number of minutes spent performing moderate and/or vigorous activity per week. Results: Women were less likely to meet PA recommendations of &amp;gt;150 minutes of weekly activity after their breast cancer diagnosis (35%) than before diagnosis (61%). African-American, lower income and less educated women were less likely to meet recommendations both pre-diagnosis and post-diagnosis, but the decline in meeting recommendations following diagnosis was consistent across these characteristics. Though the majority of women (63%) decreased activity post-diagnosis, 19% increased and 18% did not change their activity levels. The average decrease in weekly minutes of PA was 230 minutes (95% CI: 190, 270). On average, African-Americans reduced their PA by more minutes than whites (276 versus 218 minutes, respectively; p-value=0.14) as did lower income compared to higher income women (311 versus 199 minutes, respectively; p-value=0.002). Compared to those with decreased post-diagnosis PA, women who were white (OR: 1.3, 95% CI: 1.0, 1.7), higher income (OR: 1.6, 95% CI: 1.2, 2.1), or higher educated (OR: 1.5, 95% CI: 0.9, 2.5) were more likely to increase activity post-diagnosis. Conclusions: After breast cancer diagnosis, cases who were African-American, had lower income, or were less educated were less likely to meet PA recommendations, less likely to increase activity, and tended to reduce PA by more minutes. Interventions should seek to increase post-diagnosis PA overall, with a focus on these subgroups. Citation Format: Brionna Hair, Sandi Hayes. Racial differences in physical activity after breast cancer diagnosis. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 137. doi:10.1158/1538-7445.AM2013-137
Romidepsin Therapy Over 5 Years in a Clinical Setting—Real-world Experience
Authors: Susan E. Bates, Larisa J. Geskin
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal